Handelsavisen
prelaunch
Companies Healthcare 6609.HK
66
6609.HK HKEX Medical Equipment, Supplies & Distribution

6609.Hk

HK$44,50
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
21,7 %
ROE
7,4 %
Net margin
20,4 %
Debt / equity
0,04
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale and distribution of medical products and services.

Business. The company operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale and distribution of medical products and services.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
7,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6609.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6609.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the medical equipment, supplies, and distribution industry, generating revenue primarily through the sale and distribution of medical products and services.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 11.49, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to 456,074,000 CNY, which supports operational flexibility and short-term obligations. The debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal reliance on debt financing.

    Profitability metrics show a return on equity (ROE) of 7.36% and a return on assets (ROA) of 6.45%, which are indicative of efficient use of equity and assets to generate returns. The net income of 83,335,000 CNY and operating income of 88,470,000 CNY reflect solid operational performance. Gross profit of 289,521,000 CNY supports a healthy margin structure, although the exact comparison to industry medians is not available in the provided data.

    The company's revenue is concentrated within the healthcare services and equipment sector, with no disclosed geographic diversification or segment breakdown. This lack of segment detail limits the ability to assess geographic or product-specific exposure.

    The company's growth trajectory is not explicitly outlined in the provided data, but the operating cash flow of 154,141,000 CNY and free cash flow of 97,458,000 CNY suggest a capacity for reinvestment or shareholder returns. Capital expenditures of -14,165,000 CNY indicate a net reduction in capital spending, which may reflect a focus on maintaining rather than expanding physical assets.

    Risk factors are assessed as low for both liquidity and dilution, with no immediate filing-based flags detected. The low dilution risk is supported by the absence of significant changes in shares outstanding between basic and diluted figures. The company's conservative leverage and strong liquidity position further mitigate financial risk.

    Recent events, including analyst estimates and filings, indicate a last actual EPS of -2.47 CNY and a last actual revenue of 232,344,000 CNY. These figures suggest a recent earnings challenge, though the broader financial snapshot indicates a generally stable and profitable operation.

    Key takeaways
    • The company maintains a strong liquidity position with a current ratio of 11.49 and significant cash reserves.
    • Profitability metrics, including ROE and ROA, indicate efficient use of equity and assets.
    • The company's capital structure is conservative, with a low debt-to-equity ratio of 0.04.
    • No immediate liquidity or dilution risks are identified, and the company's financial position appears stable.
    • The company's recent earnings performance shows a negative EPS, but overall financial health remains robust.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$44,50
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    HK$1.13B
    Net cash
    HK$413.4M
    Current ratio
    11.5
    Debt / equity
    0.0
    ROA
    6.5%
    ROE
    7.4%
    Cash conversion
    185.0%
    CapEx / revenue
    -3.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin21,7 %Above P75
    Net Margin20,4 %Above P75
    ROE7,4 %Above median
    Capex / Rev-3,5 %Above median
    D/E0,04Above median
    Cash Conv1,85Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 6609.HK Market data — financials · 2026-05-27
    • Shanghai HeartCare Medical Technology Corp Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6609.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage